Resveratrol: One molecule, many targets

Resveratrol is one of the numerous polyphenolic compounds found in several vegetal sources. In recent years, the interest in this molecule has increased exponentially following the major findings that resveratrol (i) is shown to be chemopreventive in some cancer models, (ii) is cardioprotective, and (iii) has positive effects on several aspects of metabolism, leading to increased lifespan in all the metazoan models tested thus far, including small mammals. Such remarkable properties have elicited a vast interest towards the identification of target proteins of resveratrol and have led to the identification of enzymes inhibited by resveratrol and others whose activation is enhanced. In the vast majority of cases, resveratrol displays inhibitory/activatory effects in the micromolar range, which is potentially attainable pharmacologically, although targets with affinities in the nanomolar range have also been reported. Here, we provide an overview of the various classes of enzymes known to be inhibited (or activated) by resveratrol. It appears that resveratrol, as a pharmacological agent, has a wide spectrum of targets. The biological activities of resveratrol may thus be dependent on its simultaneous activity on multiple molecular targets. © 2008 IUBMB IUBMB Life, 60(5): 323–332, 2008

[1]  Kimura Yoshiyuki,et al.  Effects of stilbenes on arachidonate metabolism in leukocytes. , 1985 .

[2]  Y. Kimura,et al.  Effects of stilbenes on arachidonate metabolism in leukocytes. , 1985, Biochimica et biophysica acta.

[3]  P. Leder,et al.  Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene , 1988, Cell.

[4]  C. Vlahos,et al.  The inhibition of phosphatidylinositol 3-kinase by quercetin and analogs. , 1992, Biochemical and biophysical research communications.

[5]  R. Geahlen,et al.  Kinase inhibitors from Polygonum cuspidatum. , 1993, Journal of natural products.

[6]  M. White,et al.  The IRS-1 signaling system. , 1994, Trends in biochemical sciences.

[7]  John Kuriyan,et al.  Crystal structure of the Src family tyrosine kinase Hck , 1997, Nature.

[8]  Norman R. Farnsworth,et al.  Cancer Chemopreventive Activity of Resveratrol, a Natural Product Derived from Grapes , 1997, Science.

[9]  J. Pezzuto,et al.  Resveratrol Inhibits Cyclooxygenase-2 Transcription and Activity in Phorbol Ester-treated Human Mammary Epithelial Cells* , 1998, The Journal of Biological Chemistry.

[10]  P. Kopp Resveratrol, a phytoestrogen found in red wine. A possible explanation for the conundrum of the 'French paradox'? , 1998, European journal of endocrinology.

[11]  M. Fontecave,et al.  Resveratrol, a remarkable inhibitor of ribonucleotide reductase , 1998, FEBS letters.

[12]  R. Snapka,et al.  DNA polymerase and topoisomerase II inhibitors from Psoralea corylifolia. , 1998, Journal of natural products.

[13]  S. Korsmeyer,et al.  Involvement of Microtubules in the Regulation of Bcl2 Phosphorylation and Apoptosis through Cyclic AMP-Dependent Protein Kinase , 1998, Molecular and Cellular Biology.

[14]  C. Ioannides,et al.  Resveratrol preferentially inhibits protein kinase C-catalyzed phosphorylation of a cofactor-independent, arginine-rich protein substrate by a novel mechanism. , 1999, Biochemistry.

[15]  Richard E. White,et al.  Resveratrol inhibits MAPK activity and nuclear translocation in coronary artery smooth muscle: reversal of endothelin‐1 stimulatory effects , 1999, FEBS letters.

[16]  M. Maccarrone,et al.  Resveratrol prevents apoptosis in K562 cells by inhibiting lipoxygenase and cyclooxygenase activity. , 1999, European journal of biochemistry.

[17]  Roger L. Williams,et al.  Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. , 2000, Molecular cell.

[18]  Y. Yamori,et al.  Resveratrol attenuates ovariectomy-induced hypertension and bone loss in stroke-prone spontaneously hypertensive rats. , 2000, Journal of nutritional science and vitaminology.

[19]  K. Christman,et al.  Effects of resveratrol on the autophosphorylation of phorbol ester-responsive protein kinases: inhibition of protein kinase D but not protein kinase C isozyme autophosphorylation. , 2000, Biochemical pharmacology.

[20]  M. Avkiran,et al.  Inhibition of protein kinase D by resveratrol. , 2001, Biochemical pharmacology.

[21]  G. Maga,et al.  Specific Structural Determinants Are Responsible for the Antioxidant Activity and the Cell Cycle Effects of Resveratrol* , 2001, The Journal of Biological Chemistry.

[22]  R. Weinberg,et al.  hSIR2SIRT1 Functions as an NAD-Dependent p53 Deacetylase , 2001, Cell.

[23]  D. Roop,et al.  Disruption of Dihydronicotinamide Riboside:Quinone Oxidoreductase 2 (NQO2) Leads to Myeloid Hyperplasia of Bone Marrow and Decreased Sensitivity to Menadione Toxicity* , 2002, The Journal of Biological Chemistry.

[24]  Phuong Chung,et al.  Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan , 2003, Nature.

[25]  L. Guarente,et al.  How does calorie restriction work? , 2003, Genes & development.

[26]  A. El-Mowafy,et al.  Resveratrol activates adenylyl-cyclase in human breast cancer cells: a novel, estrogen receptor-independent cytostatic mechanism. , 2003, Carcinogenesis.

[27]  L. Goodyear,et al.  AMP-activated protein kinase and muscle glucose uptake. , 2003, Acta physiologica Scandinavica.

[28]  K. Subbaramaiah,et al.  Cyclooxygenase 2: a molecular target for cancer prevention and treatment. , 2003, Trends in pharmacological sciences.

[29]  S. Slater,et al.  Inhibition of protein kinase C by resveratrol. , 2003, Biochimica et biophysica acta.

[30]  Steven P. Gygi,et al.  Stress-Dependent Regulation of FOXO Transcription Factors by the SIRT1 Deacetylase , 2004, Science.

[31]  J. Wood,et al.  Sirtuin activators mimic caloric restriction and delay ageing in metazoans , 2004, Nature.

[32]  Zhongtao Zhang,et al.  Crystal structure of quinone reductase 2 in complex with resveratrol. , 2004, Biochemistry.

[33]  L. Stivala,et al.  Resveratrol is a Peroxidase-mediated Inactivator of COX-1 but Not COX-2 , 2004, Journal of Biological Chemistry.

[34]  S. Helfand,et al.  An accelerated assay for the identification of lifespan-extending interventions in Drosophila melanogaster. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[35]  N. Seeram,et al.  Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. , 2004, Anticancer research.

[36]  T. Walle,et al.  HIGH ABSORPTION BUT VERY LOW BIOAVAILABILITY OF ORAL RESVERATROL IN HUMANS , 2004, Drug Metabolism and Disposition.

[37]  C. O'Brian,et al.  Resveratrol Antagonizes EGFR-Dependent Erk1/2 Activation in Human Androgen-Independent Prostate Cancer Cells with Associated Isozyme-Selective PKCα Inhibition , 2004, Investigational New Drugs.

[38]  Zhongtao Zhang,et al.  Identification and purification of resveratrol targeting proteins using immobilized resveratrol affinity chromatography. , 2004, Biochemical and biophysical research communications.

[39]  L. Guarente,et al.  Calorie Restriction— the SIR2 Connection , 2005, Cell.

[40]  Brian C. Smith,et al.  Mechanism of Human SIRT1 Activation by Resveratrol* , 2005, Journal of Biological Chemistry.

[41]  Michael Karin,et al.  NF-kappaB: linking inflammation and immunity to cancer development and progression. , 2005, Nature reviews. Immunology.

[42]  Y. Bignon,et al.  Resveratrol and breast cancer chemoprevention: molecular mechanisms. , 2005, Molecular nutrition & food research.

[43]  Steven P Gygi,et al.  Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. , 2005, Nature.

[44]  Christian Néri,et al.  Resveratrol rescues mutant polyglutamine cytotoxicity in nematode and mammalian neurons , 2005, Nature Genetics.

[45]  M. Provinciali,et al.  Effect of resveratrol on the development of spontaneous mammary tumors in HER‐2/neu transgenic mice , 2005, International journal of cancer.

[46]  S. Fields,et al.  Genes determining yeast replicative life span in a long-lived genetic background , 2005, Mechanisms of Ageing and Development.

[47]  S. Fields,et al.  Substrate-specific Activation of Sirtuins by Resveratrol* , 2005, Journal of Biological Chemistry.

[48]  Yiling Lu,et al.  Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery , 2005, Nature Reviews Drug Discovery.

[49]  M. J. Atten,et al.  Resveratrol regulates cellular PKC alpha and delta to inhibit growth and induce apoptosis in gastric cancer cells. , 2005, Investigational new drugs.

[50]  J. K. Kundu,et al.  Resveratrol inhibits phorbol ester-induced expression of COX-2 and activation of NF-κB in mouse skin by blocking IκB kinase activity , 2006 .

[51]  Joseph A. Baur,et al.  Therapeutic potential of resveratrol: the in vivo evidence , 2006, Nature Reviews Drug Discovery.

[52]  B. Aggarwal,et al.  Inflammation and cancer: how hot is the link? , 2006, Biochemical pharmacology.

[53]  Antonino Cattaneo,et al.  Resveratrol Prolongs Lifespan and Retards the Onset of Age-Related Markers in a Short-Lived Vertebrate , 2006, Current Biology.

[54]  Mengwei Zang,et al.  Polyphenols Stimulate AMP-Activated Protein Kinase, Lower Lipids, and Inhibit Accelerated Atherosclerosis in Diabetic LDL Receptor–Deficient Mice , 2006, Diabetes.

[55]  P. Puigserver,et al.  Resveratrol Improves Mitochondrial Function and Protects against Metabolic Disease by Activating SIRT1 and PGC-1α , 2006, Cell.

[56]  R. Pestell,et al.  SIRT1 and endocrine signaling , 2006, Trends in Endocrinology & Metabolism.

[57]  P. Puigserver,et al.  Resveratrol improves health and survival of mice on a high-calorie diet , 2006, Nature.

[58]  Jiandi Zhang Resveratrol inhibits insulin responses in a SirT1-independent pathway. , 2006, The Biochemical journal.

[59]  Á. Tósaki,et al.  Potentiation of a Survival Signal in the Ischemic Heart by Resveratrol through p38 Mitogen-Activated Protein Kinase/Mitogen- and Stress-Activated Protein Kinase 1/cAMP Response Element-Binding Protein Signaling , 2006, Journal of Pharmacology and Experimental Therapeutics.

[60]  H. Duplain Salvage of ischemic myocardium: a focus on JNK. , 2006, Advances in experimental medicine and biology.

[61]  J. K. Kundu,et al.  Resveratrol inhibits phorbol ester-induced expression of COX-2 and activation of NF-kappaB in mouse skin by blocking IkappaB kinase activity. , 2006, Carcinogenesis.

[62]  Meihong Lin,et al.  Blockage of oncostatin M-induced LDL receptor gene transcription by a dominant-negative mutant of C/EBPbeta. , 2006, The Biochemical journal.

[63]  M. Nihal,et al.  Resveratrol-caused apoptosis of human prostate carcinoma LNCaP cells is mediated via modulation of phosphatidylinositol 3′-kinase/Akt pathway and Bcl-2 family proteins , 2006, Molecular Cancer Therapeutics.

[64]  L. Guarente Sirtuins as potential targets for metabolic syndrome , 2006, Nature.

[65]  J. K. Kundu,et al.  Resveratrol modulates phorbol ester-induced pro-inflammatory signal transduction pathways in mouse skin in vivo: NF-kappaB and AP-1 as prime targets. , 2006, Biochemical pharmacology.

[66]  E. Asselin,et al.  Resveratrol interferes with AKT activity and triggers apoptosis in human uterine cancer cells , 2006, Molecular Cancer.

[67]  Shiuan Chen,et al.  The red wine polyphenol resveratrol displays bilevel inhibition on aromatase in breast cancer cells. , 2006, Toxicological sciences : an official journal of the Society of Toxicology.

[68]  J. Turkson,et al.  Resveratrol inhibits Src and Stat3 signaling and induces the apoptosis of malignant cells containing activated Stat3 protein , 2006, Molecular Cancer Therapeutics.

[69]  L. Pirola,et al.  Resveratrol is a class IA phosphoinositide 3-kinase inhibitor. , 2007, The Biochemical journal.

[70]  Walter Jaeger,et al.  'Bridged' stilbene derivatives as selective cyclooxygenase-1 inhibitors. , 2007, Bioorganic & medicinal chemistry.

[71]  Q. Zhai,et al.  SIRT1 improves insulin sensitivity under insulin-resistant conditions by repressing PTP1B. , 2007, Cell metabolism.

[72]  Yun Wang,et al.  Pharmacological concentration of resveratrol suppresses aromatase in JEG-3 cells. , 2007, Toxicology letters.

[73]  J. Ha,et al.  Resveratrol stimulates glucose transport in C2C12 myotubes by activating AMP-activated protein kinase , 2007, Experimental & Molecular Medicine.

[74]  D. Sinclair,et al.  Design and synthesis of compounds that extend yeast replicative lifespan , 2007, Aging cell.

[75]  J. Crowell,et al.  Phase I Dose Escalation Pharmacokinetic Study in Healthy Volunteers of Resveratrol, a Potential Cancer Chemopreventive Agent , 2007, Cancer Epidemiology Biomarkers & Prevention.

[76]  L. Partridge,et al.  Effects of resveratrol on lifespan in Drosophila melanogaster and Caenorhabditis elegans , 2007, Mechanisms of Ageing and Development.

[77]  L. Guarente,et al.  SIR2: a potential target for calorie restriction mimetics. , 2007, Trends in molecular medicine.

[78]  Z. Ungvari,et al.  Resveratrol Increases Vascular Oxidative Stress Resistance , 2007, American journal of physiology. Heart and circulatory physiology.

[79]  G. Sherbet,et al.  Resveratrol-induced apoptosis in human T-cell acute lymphoblastic leukaemia MOLT-4 cells. , 2007, Biochemical pharmacology.

[80]  T. Szekeres,et al.  N-hydroxy-N'-(3,4,5-trimethoxyphenyl)-3,4,5-trimethoxy-benzamidine, a novel resveratrol analog, inhibits ribonucleotide reductase in HL-60 human promyelocytic leukemia cells: synergistic antitumor activity with arabinofuranosylcytosine. , 2007, International journal of oncology.

[81]  B. Kennedy,et al.  Does resveratrol activate yeast Sir2 in vivo? , 2007, Aging cell.